Can Immune-Boosting drugs tame recurrent endometrial cancer?
NCT ID NCT02912572
First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time
Summary
This trial investigates whether the immunotherapy drug avelumab, given alone or combined with talazoparib or axitinib, can shrink tumors or slow disease progression in women with recurrent or persistent endometrial cancer. Participants have specific tumor types, including those with high microsatellite instability (MSI-H) or POLE mutations. The study aims to see if these targeted combinations offer a new way to control the disease when standard treatments have stopped working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- avelumab, alone or combined with talazoparib or axitinib
- What this could lead to
- If successful, these drug combinations could offer new treatment options for women with recurrent endometrial cancer that has not responded to standard therapy.
- What could go wrong
- This is a mid-stage trial with a relatively small number of participants. The drugs may cause side effects, and not all patients may benefit. Results will need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- New drug combo targets Hard-to-Treat cancers in early trial
- Could a pill keep endometrial cancer at bay? new study tests rucaparib
- New pill targets Hard-to-Treat cancers in early human test
- New pill takes aim at Hard-to-Treat cancers
- Could your own tumor cells fight cancer? new trial tests immune cell therapy